Phytochemicals are typically natural bioactive compounds or metabolites produced by plants. Phytochemical-loaded nanocarrier systems, designed to overcome bioavailability limitations and enhance therapeutic effects, have garnered significant attention in recent years. The coronavirus disease 2019 (COVID-19) pandemic has intensified interest in the therapeutic application of phytochemicals to combat viral infections. This review explores nanoparticle-based treatment strategies incorporating phytochemicals for antiviral application, highlighting their demonstrated antiviral mechanisms. It specifically examines the antiviral activities of phytochemical-loaded nanosystems against (i) influenza virus (IAV), respiratory syncytial virus (RSV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); (ii) mosquito-borne viruses [dengue (DENV), Zika (ZIKV), and Chikungunya (CHIKV)]; and (iii) sexually transmitted/blood borne viruses [e.g. herpes simplex virus (HSV), human papillomavirus (HPV), and human immunodeficiency virus (HIV)]. Furthermore, this review highlights the emerging role of these nanosystems in photodynamic therapy (PDT)-mediated attenuation of viral proliferation, and offers a perspective on the future directions of research in this promising area of multimodal therapeutic approach.

Keywords

Phytochemical; antiviral; infection; nanoparticles; photodynamic therapy; virus.

1. Ahn, K. (2017). The worldwide trend of using botanical drugs and strategies for developing global drugs. BMB Reports, 50(3), 111–116. https://doi.org/10.5483/bmbrep.2017.50.3.221
2. Sun, Y., & Qian, J. (2021). Botanical drug clinical trial: common issues and future options. Acta Pharmacologica Sinica B, 11(1), 300–303. https://doi.org/10.1016/j.apsb.2020.08.003
3. Wu, C., Lee, S. L., Taylor, C., & et al. (2020). Scientific and regulatory approach to botanical drug development: a U.S. FDA perspective. Journal of Natural Products, 83(2), 552–562. https://doi.org/10.1021/acs.jnatprod.9b00949
4. Kumar, A., N, P., Kumar, M., & et al. (2023). Major phytochemicals: recent advances in health benefits and extraction method. Molecules, 28(2), Article 887. https://doi.org/10.3390/molecules28020887
5. Rodríguez-Negrete, E. V., Morales-González, Á., Madrigal-Santillán, E. O., & et al. (2024). Phytochemicals and their usefulness in the maintenance of health. Plants, 13(4), Article 523. https://doi.org/10.3390/plants13040523
6. Choudhari, A. S., Mandave, P. C., Deshpande, M., & et al. (2019). Phytochemicals in cancer treatment: from preclinical studies to clinical practice. Frontiers in Pharmacology, 10, Article 1614. https://doi.org/10.3389/fphar.2019.01614
7. Laka, K., Makgoo, L., & Mbita, Z. (2022). Cholesterol-lowering phytochemicals: targeting the mevalonate pathway for anticancer interventions. Frontiers in Genetics, 13, Article 841639. https://doi.org/10.3389/fgene.2022.841639
8. Dubey, P., & Pandey, K. B. (2023). Neurotransmitter modulation by phytochemicals. In C. Egbuna & M. Rudrapal (Eds.), Phytochemical drug discovery for central nervous system disorders: Biochemistry and therapeutic effects (p. 311–325). John Wiley & Sons.
9. Gonfa, Y. H., Tessema, F. B., Bachheti, A., & et al. (2023). Anti-inflammatory activity of phytochemicals from medicinal plants and their nanoparticles: a review. Current Research in Biotechnology, 6, Article 100152. https://doi.org/10.1016/j.crbiot.2023.100152
10. Parham, S., Kharazi, A. Z., Bakhsheshi-Rad, H. R., & et al. (2020). Antioxidant, antimicrobial and antiviral properties of herbal materials. Antioxidants, 9(12), Article 1309. https://doi.org/10.3390/antiox9121309
11. Díaz-Puertas, R., Álvarez-Martínez, F. J., Falco, A., & et al. (2023). Phytochemical-based nanomaterials against antibiotic-resistant bacteria: an updated review. Polymers, 15(6), Article 1392. https://doi.org/10.3390/polym15061392
12. Behl, T., Rocchetti, G., Chadha, S., & et al. (2021). Phytochemicals from plant foods as potential source of antiviral agents: an overview. Pharmaceuticals, 14(4), Article 381. https://doi.org/10.3390/ph14040381
13. Kapoor, R., Sharma, B., & Kanwar, S. S. (2017). Antiviral phytochemicals: an overview. Biochemistry and physiology. Biochemistry & Physiology: Open Access, 6(2). https://doi.org/10.4172/2168-9652.1000220
14. Patra, J. K., Das, G., Bose, S., & et al. (2020). Star anise (Illicium verum): chemical compounds, antiviral properties, and clinical relevance. Phytotherapy Research, 34(6), 1248–1267. https://doi.org/10.1002/ptr.6614
15. Watkins, R., Wu, L., Zhang, C., & et al. (2015). Natural product-based nanomedicine: recent advances and issues. International Journal of Nanomedicine, 10, 6055–6074. https://doi.org/10.2147/IJN.S92162
16. McClements, D. J. (2020). Advances in nanoparticle and microparticle delivery systems for increasing the dispersibility, stability, and bioactivity of phytochemicals. Biotechnology Advances, 38, Article 107287. https://doi.org/10.1016/j.biotechadv.2018.08.004
17. Vanti, G. (2021). Recent strategies in nanodelivery systems for natural products: a review. Environmental Chemistry Letters, 19(6), 4311–4326. https://doi.org/10.1007/s10311-021-01276-x
18. Rahman, H. S., Othman, H. H., Hammadi, N. I., & et al. (2020). Novel drug delivery systems for loading of natural plant extracts and their biomedical applications. International Journal of Nanomedicine, 15, 2439–2483. https://doi.org/10.2147/IJN.S227805
19. Campora, S., & Ghersi, G. (2022). Recent developments and applications of smart nanoparticles in biomedicine. Nanotechnology Reviews, 11(1), 2595–2631. https://doi.org/10.1515/ntrev-2022-0148
20. Loo, Y. S., Zahid, N. I., Madheswaran, T., & et al. (2022). Recent advances in the development of multifunctional lipid-based nanoparticles for co-delivery, combination treatment strategies, and theranostics in breast and lung cancer. Journal of Drug Delivery Science and Technology, 71, Article 103300. https://doi.org/10.1016/j.jddst.2022.103300
21. Leu, J. S. L., Teoh, J. J. X., Ling, A. L. Q., & et al. (2023). Recent advances in the development of liquid crystalline nanoparticles as drug delivery systems. Pharmaceutics, 15(5), Article 1421. https://doi.org/10.3390/pharmaceutics15051421
22. Namiot, E. D., Sokolov, A. V., Chubarev, V. N., & et al. (2023). Nanoparticles in clinical trials: analysis of clinical trials, FDA approvals and use for COVID-19 vaccines. International Journal of Molecular Sciences, 24(1), Article 787. https://doi.org/10.3390/ijms24010787
23. Jiménez-Escobar, M. P., Pascual-Pineda, L. A., Vernon-Carter, E. J., & et al. (2021). Enhanced $\beta$-carotene encapsulation and protection in self-assembled lyotropic liquid crystal structures. LWT, 135, Article 110056. https://doi.org/10.1016/j.lwt.2020.110056
24. Jain, A., Sharma G., Kushwah, V., & et al. (2018). Beta carotene-loaded zein nanoparticles to improve the biopharmaceutical attributes and to abolish the toxicity of methotrexate: a preclinical study for breast cancer. Artificial Cells, Nanomedicine, and Biotechnology, 46(Suppl. 1), 402–412. https://doi.org/10.1080/21691401.2018.1428811
25. Jain, A., Sharma, G., Thakur, K., & et al. (2019). Beta-carotene-encapsulated solid lipid nanoparticles (BC-SLNs) as promising vehicle for cancer: an investigative assessment. AAPS PharmSciTech, 20(3), Article 100. https://doi.org/10.1208/s12249-019-1301-7
26. Farcas, C. G., Dehelean, C., Pinzaru, I. A., & et al. (2020). Thermosensitive betulinic acid-loaded magnetoliposomes: a promising antitumor potential for highly aggressive human breast adenocarcinoma cells under hyperthermic conditions. International Journal of Nanomedicine, 15, 8175–8200. https://doi.org/10.2147/IJN.S269630
27. Godugu, C., Patel, A. R., Doddapaneni, R., & et al. (2014). Approaches to improve the oral bioavailability and effects of novel anticancer drugs berberine and betulinic acid. PLOS ONE, 9(3), Article e89919. https://doi.org/10.1371/journal.pone.0089919
28. Bharali, D. J., Siddiqui, I. A., Adhami, V. M., & et al. (2011). Nanoparticle delivery of natural products in the prevention and treatment of cancers: current status and future prospects. Cancers, 3(4), 4024–4045. https://doi.org/10.3390/cancers3044024
29. Thapa, R., Khan, G. M., Parajuli-Baral, K., & et al. (2013). Herbal medicine incorporated nanoparticles: advancements in herbal treatment. Asian Journal of Biomedical and Pharmaceutical Sciences, 3(24), 7–14.
30. Wang, S., Su, R., Nie, S., & et al. (2014). Application of nanotechnology in improving bioavailability and bioactivity of diet-derived phytochemicals. Journal of Nutritional Biochemistry, 25(4), 363–376. https://doi.org/10.1016/j.jnutbio.2013.10.002
31. Ho, C. H., Chu, P. Y., Peng, S. L., & et al. (2020). The development of hyaluronan/fucoidan-based nanoparticles as macrophages targeting an epigallocatechin-3-gallate delivery system. International Journal of Molecular Sciences, 21(17), Article 6327. https://doi.org/10.3390/ijms21176327
32. Shakeri, A., & Sahebkar, A. (2016). Opinion paper: nanotechnology: a successful approach to improve oral bioavailability of phytochemicals. Recent Patents on Drug Delivery & Formulation, 10(1), 4–6. https://doi.org/10.2174/1872211309666150611120724
33. Hanafy, N. A. N., Sheashaa, R. F., Moussa, E. A., & et al. (2023). Potential of curcumin and niacin-loaded targeted chitosan coated liposomes to activate autophagy in hepatocellular carcinoma cells: an in vitro evaluation in HePG2 cell line. International Journal of Biological Macromolecules, 245, Article 125572. https://doi.org/10.1016/j.ijbiomac.2023.125572
34. Salehi, B., Del Prado-Audelo, M. L., Cortés, H., & et al. (2020). Therapeutic applications of curcumin nanomedicine formulations in cardiovascular diseases. Journal of Clinical Medicine, 9(3), Article 746. https://doi.org/10.3390/jcm9030746
35. Gutberlet, B., Preis, E., Roschenko, V., & et al. (2023). Photothermally controlled drug release of poly(D,L-lactide) nanofibers loaded with indocyanine green and curcumin for efficient antimicrobial photodynamic therapy. Pharmaceutics, 15(2), Article 327. https://doi.org/10.3390/pharmaceutics15020327
36. Rodenak-Kladniew, B., Scioli Montoto, S., Sbaraglini, M. L., & et al. (2019). Hybrid Ofloxacin/eugenol co-loaded solid lipid nanoparticles with enhanced and targetable antimicrobial properties. International Journal of Pharmaceutics, 569, Article 118575. https://doi.org/10.1016/j.ijpharm.2019.118575
37. Yarian, F., Yousefpoor, Y., Hatami, S., & et al. (2023). Comparison effects of alginate nanoparticles containing Syzygium aromaticum essential oil and eugenol on apoptotic regulator genes and viability of A-375 and MCF-7 cancer cell lines. BioNanoscience, 13(3), 911–919. https://doi.org/10.1007/s12668-023-01121-1
38. Arghand, N., Reiisi, S., Karimi, B., & et al. (2024). Biosynthesis of nanocomposite alginate-chitosan loaded with silver nanoparticles coated with eugenol/quercetin to enhance wound healing. BioNanoscience, 14(5), 5149–5166. https://doi.org/10.1007/s12668-024-01479-w
39. Ganesan, P., Ramalingam, P., Karthivashan, G., & et al. (2018). Recent developments in solid lipid nanoparticle and surface-modified solid lipid nanoparticle delivery systems for oral delivery of phyto-bioactive compounds in various chronic diseases. International Journal of Nanomedicine, 13, 1569–1583. https://doi.org/10.2147/IJN.S155593
40. Bao, R., Wang, Q.-L., Li, R., & et al. (2020). Improved oral bioavailability and target delivery of 6-shogaol via vitamin E TPGS-modified liposomes: preparation, in-vitro and in-vivo characterizations. Journal of Drug Delivery Science and Technology, 59, Article 101842. https://doi.org/10.1016/j.jddst.2020.101842
41. Yang, M., Jiang, G., Li, Y., & et al. (2024). Paeoniflorin loaded liposomes modified with glycyrrhetinic acid for liver-targeting: preparation, characterization, and pharmacokinetic study. Pharmaceutical Development and Technology, 29(3), 176–186. https://doi.org/10.1080/10837450.2024.2319738
42. Li, S., Guo, J., Tian, Z., & et al. (2021). Piperine-loaded glycyrrhizic acid- and PLGA-based nanoparticles modified with transferrin for antitumor: piperine-loaded glycyrrhizic acid- and PLGA-based nanoparticles. AAPS PharmSciTech, 22(7), Article 239. https://doi.org/10.1208/s12249-021-02123-6
43. Liu, H., Li, K., Lan, L., & et al. (2014). Double-layered hyaluronic acid/stearic acid-modified polyethyleneimine nanoparticles encapsulating (−)-gossypol: a nanocarrier for chiral anticancer drugs. Journal of Materials Chemistry B, 2(32), 5238–5248. https://doi.org/10.1039/C4TB00539B
44. Heleg-Shabtai, V., Aizen, R., Orbach, R., & et al. (2015). Gossypol-cross-linked boronic acid-modified hydrogels: a functional matrix for the controlled release of an anticancer drug. Langmuir, 31(7), 2237–2242. https://doi.org/10.1021/la504959d
45. Singh, P., & Sahoo, S. K. (2022). Piperlongumine loaded PLGA nanoparticles inhibit cancer stem-like cells through modulation of STAT3 in mammosphere model of triple negative breast cancer. International Journal of Pharmaceutics, 616, Article 121526. https://doi.org/10.1016/j.ijpharm.2022.121526
46. Parveen, S., Kumar, S., Pal, S., & et al. (2023). Enhanced therapeutic efficacy of piperlongumine for cancer treatment using nano-liposomes mediated delivery. International Journal of Pharmaceutics, 643, Article 123212. https://doi.org/10.1016/j.ijpharm.2023.123212
47. Liu, Q., Zhao, D., Zhu, X., & et al. (2017). Coloaded nanoparticles of paclitaxel and piperlongumine for enhancing synergistic antitumor activities and reducing toxicity. Journal of Pharmaceutical Sciences, 106(10), 3066–3075. https://doi.org/10.1016/j.xphs.2017.05.027
48. Liu, C. H., Lin, C. C., Hsu, W. C., & et al. (2017). Highly bioavailable silibinin nanoparticles inhibit HCV infection. Gut, 66(10), 1853–1861. https://doi.org/10.1136/gutjnl-2016-312019
49. Loutfy, S. A., Abdel-Salam, A. I., Moatasim, Y., & et al. (2022). Antiviral activity of chitosan nanoparticles encapsulating silymarin (sil-CNPs) against SARS-CoV-2 (in silico and in vitro study). RSC Advances, 12(25), 15775–15786. https://doi.org/10.1039/d2ra00905f
50. Gupta, P., Sharma, S., Neupane, Y. R., & et al. (2023). Co-delivery of exemestane and thymoquinone via nanostructured lipid carriers for efficient breast cancer therapy. Journal of Drug Delivery Science and Technology, 88, Article 104892. https://doi.org/10.1016/j.jddst.2023.104892
51. Gheybi, F., Khooei, A., Hoseinian, A., & et al. (2023). Alleviation of acetaminophen-induced liver failure using silibinin nanoliposomes: an in vivo study. Biochemical and Biophysical Research Communications, 676, 103–108. https://doi.org/10.1016/j.bbrc.2023.07.045
52. Negi, P., Sharma, I., Hemrajani, C., & et al. (2019). Thymoquinone-loaded lipid vesicles: a promising nanomedicine for psoriasis. BMC Complementary Medicine and Therapies, 19(1), Article 334. https://doi.org/10.1186/s12906-019-2675-5
53. Shabani, H., Karami, M. H., Kolour, J., & et al. (2023). Anticancer activity of thymoquinone against breast cancer cells: mechanisms of action and delivery approaches. Biomedicine & Pharmacotherapy, 165, Article 114972. https://doi.org/10.1016/j.biopha.2023.114972
54. Ballout, F., Habli, Z., Rahal, O. N., & et al. (2018). Thymoquinone-based nanotechnology for cancer therapy: promises and challenges. Drug Discovery Today, 23(5), 1089–1098. https://doi.org/10.1016/j.drudis.2018.01.043
55. El-Far, A. H., Al Jaouni, S. K., Li, W., & et al. (2018). Protective roles of thymoquinone nanoformulations: potential nanonutraceuticals in human diseases. Nutrients, 10(10), Article 1369. https://doi.org/10.3390/nu10101369
56. Zhao, Z., Ukidve, A., Kim, J., & et al. (2020). Targeting strategies for tissue-specific drug delivery. Cell, 181(1), 151–167. https://doi.org/10.1016/j.cell.2020.02.001
57. Attia, M. F., Anton, N., Wallyn, J., & et al. (2019). An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites. Journal of Pharmacy and Pharmacology, 71(8), 1185–1198. https://doi.org/10.1111/jphp.13098
58. Nazaruk, E., Szlęzak, M., Górecka, E., & et al. (2014). Design and assembly of pH-sensitive lipidic cubic phase matrices for drug release. Langmuir, 30(5), 1383–1390. https://doi.org/10.1021/la403694e
59. Negrini, R., Fong, W. K., Boyd, B. J., & et al. (2015). pH-responsive lyotropic liquid crystals and their potential therapeutic role in cancer treatment. Chemical Communications, 51(30), 6671–6674. https://doi.org/10.1039/c4cc10274f
60. Chen, C., Zhou, Y., Chen, C., & et al. (2022). Quantification of available ligand density on the surface of targeted liposomal nanomedicines at the single-particle level. ACS Nano, 16(4), 6886–6897. https://doi.org/10.1021/acsnano.2c02084
61. Barui, A. K., Oh, J. Y., Jana, B., & et al. (2020). Cancer-targeted nanomedicine: overcoming the barrier of the protein corona. Advanced Therapeutics, 3(1), Article 1900124. https://doi.org/10.1002/adtp.201900124
62. Jayan, H., Maria Leena, M., Sivakama Sundari, S. K., & et al. (2019). Improvement of bioavailability for resveratrol through encapsulation in zein using electrospraying technique. Journal of Functional Foods, 57, 417–424. https://doi.org/10.1016/j.jff.2019.04.007
63. Tsichlis, I., Manou, A.-P., Manolopoulou, V., & et al. (2023). Development of liposomal and liquid crystalline lipidic nanoparticles with non-ionic surfactants for quercetin incorporation. Materials, 16(16), Article 5509. https://doi.org/10.3390/ma16165509
64. Loregian, A., Mercorelli, B., Nannetti, G., & et al. (2014). Antiviral strategies against influenza virus: towards new therapeutic approaches. Cellular and Molecular Life Sciences, 71(19), 3659–3683. https://doi.org/10.1007/s00018-014-1615-2
65. Abookleesh, F. L., Al-Anzi, B. S., & Ullah, A. (2022). Potential antiviral action of alkaloids. Molecules, 27(3), Article 903. https://doi.org/10.3390/molecules27030903
66. Elste, J., Kumari, S., Sharma, N., & et al. (2023). Plant cell-engineered gold nanoparticles conjugated to quercetin inhibit SARS-CoV-2 and HSV-1 entry. International Journal of Molecular Sciences, 24(19), Article 14792. https://doi.org/10.3390/ijms241914792
67. LeBlanc, E. V., & Colpitts, C. C. (2022). The green tea catechin EGCG provides proof-of-concept for a pan-coronavirus attachment inhibitor. Scientific Reports, 12(1), Article 12899. https://doi.org/10.1038/s41598-022-17088-0
68. Zhang, Z., Zhang, X., Bi, K., & et al. (2021). Potential protective mechanisms of green tea polyphenol EGCG against COVID-19. Trends in Food Science & Technology, 114, 11–24. https://doi.org/10.1016/j.tifs.2021.05.023
69. Kandeil, A., Mostafa, A., Kutkat, O., & et al. (2021). Bioactive polyphenolic compounds showing strong antiviral activities against severe acute respiratory syndrome coronavirus 2. Pathogens, 10(6), Article 758. https://doi.org/10.3390/pathogens10060758
70. Berretta, A. A., Silveira, M. A. D., Cóndor Capcha, J. M., & et al. (2020). Propolis and its potential against SARS-CoV-2 infection mechanisms and COVID-19 disease. Biomedicine & Pharmacotherapy, 131, Article 110622. https://doi.org/10.1016/j.biopha.2020.110622
71. McCarty, M. F., & DiNicolantonio, J. J. (2020). Nutraceuticals have potential for boosting the type 1 interferon response to RNA viruses including influenza and coronavirus. Progress in Cardiovascular Diseases, 63(3), 383–385. https://doi.org/10.1016/j.pcad.2020.02.007
72. Li, R., Han, Q., Li, X., & et al. (2024). Natural product-derived phytochemicals for influenza a virus (H1N1) prevention and treatment. Molecules, 29(10), Article 2371. https://doi.org/10.3390/molecules29102371
73. Dawood, F. S., Chung, J. R., Kim, S. S., & et al. (2020). Interim estimates of 2019–20 seasonal influenza vaccine effectiveness - United States, February 2020. MMWR. Morbidity and Mortality Weekly Report, 69(7), 177–182. https://doi.org/10.15585/mmwr.mm6907a1
74. Adlhoch, C., Sneiderman, M., Martinuka, O., & et al. (2021). Spotlight influenza: the 2019/20 influenza season and the impact of COVID-19 on influenza surveillance in the WHO European region. Eurosurveillance, 26(40), Article 2100077. https://doi.org/10.2807/1560-7917.ES.2021.26.40.2100077
75. van de Witte, S. V., Nauta, J., Giezeman-Smits, K. M., & et al. (2012). Trivalent inactivated subunit influenza vaccine Influvac®: 30-year experience of safety and immunogenicity. Trials in Vaccinology, 1, 42–48. https://doi.org/10.1016/j.trivac.2012.10.001
76. Chadha, M., Hirve, S., Bancej, C., & et al. (2020). Human respiratory syncytial virus and influenza seasonality patterns-early findings from the WHO global respiratory syncytial virus surveillance. Influenza and Other Respiratory Viruses, 14(6), 638–646. https://doi.org/10.1111/irv.12726
77. Goyal, R., Gautam, R. K., Chopra, H., & et al. (2022). Comparative highlights on MERS-CoV, SARS-CoV-1, SARS-CoV-2, and NEO-CoV. EXCLI Journal, 21, 1245–1272. https://doi.org/10.17179/excli2022-5355
78. Kaku, Y., Uriu, K., Okumura, K., & et al. (2024). Virological characteristics of the SARS-CoV-2 KP.3.1.1 variant. The Lancet Infectious Diseases, 24(10), e609. https://doi.org/10.1016/S1473-3099(24)00505-X
79. Saadh, M. J., & Aldalaen, S. M. (2021). Inhibitory effects of epigallocatechin gallate (EGCG) combined with zinc sulfate and silver nanoparticles on avian influenza a virus subtype H5N1. European Review for Medical and Pharmacological Sciences, 25(6), 2630–2636. https://doi.org/10.26355/eurrev_202103_25427
80. Saadh, M. J., Aggag, M. M., Alboghdadly, A., & et al. (2021). Silver nanoparticles with epigallocatechingallate and zinc sulphate significantly inhibits avian influenza a virus H9N2. Microbial Pathogenesis, 158, Article 105071. https://doi.org/10.1016/j.micpath.2021.105071
81. El-Sayed, H., Mady, W., Saif, M., & et al. (1999). Efficacy of quercetin nanoparticles as a new antiviral against H5N1 influenza virus replication. Assiut Veterinary Medical Journal, 64(159). https://doi.org/10.21608/avmj.2018.168998
82. AbouAitah, K., Swiderska-Sroda, A., Kandeil, A., & et al. (2020). Virucidal action against avian influenza H5N1 virus and immunomodulatory effects of nanoformulations consisting of mesoporous silica nanoparticles loaded with natural prodrugs. International Journal of Nanomedicine, 15, 5181–5202. https://doi.org/10.2147/IJN.S247692
83. Sadatrasul, M. S., Fiezi, N., Ghasemian, N., & et al. (2017). Oil-in-water emulsion formulated with eucalyptus leaves extract inhibit influenza virus binding and replication in vitro. AIMS Microbiology, 3(4), 899–907. https://doi.org/10.3934/microbiol.2017.4.899
84. Li, C. Z., Chang, H. M., Hsu, W. L., & et al. (2022). Curcumin-loaded oil-free self-assembled micelles inhibit the influenza a virus activity and the solidification of curcumin-loaded micelles for pharmaceutical applications. Pharmaceutics, 14(11), Article 2422. https://doi.org/10.3390/pharmaceutics14112422
85. Fatima, M., Zaidi, N. U., Amraiz, D., & et al. (2016). In vitro antiviral activity of Cinnamomum cassia and its nanoparticles against H7N3 influenza a virus. Journal of Microbiology and Biotechnology, 26(1), 151–159. https://doi.org/10.4014/jmb.1508.08024
86. Sreekanth, T. V. M., Nagajyothi, P. C., Muthuraman, P., & et al. (2018). Ultra-sonication-assisted silver nanoparticles using Panax ginseng root extract and their anti-cancer and antiviral activities. Journal of Photochemistry and Photobiology B: Biology, 188, 6–11. https://doi.org/10.1016/j.jphotobiol.2018.08.013
87. Ahmad, M. S., Musaddiq, H., & Shahzad, M. I. (2020). Anti MRSA and antiviral evaluation of nano silver against avian influenza virus. Frontiers in Chemical Sciences, 1(2), 59–66. https://doi.org/10.52700/fcs.v1i2.11
88. Yang, X. X., Li, C. M., & Huang, C. Z. (2016). Curcumin modified silver nanoparticles for highly efficient inhibition of respiratory syncytial virus infection. Nanoscale, 8(5), 3040–3048. https://doi.org/10.1039/C5NR07918G
89. Yang, X. X., Li, C. M., Li, Y. F., & et al. (2017). Synergistic antiviral effect of curcumin functionalized graphene oxide against respiratory syncytial virus infection. Nanoscale, 9(41), 16086–16092. https://doi.org/10.1039/C7NR06520E
90. Dourado, D., Freire, D. T., Pereira, D. T., & et al. (2021). Will curcumin nanosystems be the next promising antiviral alternatives in COVID-19 treatment trials? Biomedicine & Pharmacotherapy, 139, Article 111578. https://doi.org/10.1016/j.biopha.2021.111578
91. Hassaniazad, M., Inchehsablagh, B. R., Kamali, H., & et al. (2020). The clinical effect of nano micelles containing curcumin as a therapeutic supplement in patients with COVID-19 and the immune responses balance changes following treatment: a structured summary of a study protocol for a randomised controlled trial. Trials, 21(1), Article 876. https://doi.org/10.1186/s13063-020-04824-y
92. Valizadeh, H., Abdolmohammadi-Vahid, S., Danshina, S., & et al. (2020). Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients. International Immunopharmacology, 89(Pt. B), Article 107088. https://doi.org/10.1016/j.intimp.2020.107088
93. Saber-Moghaddam, N., Salari, S., Hejazi, S., & et al. (2021). Oral nano-curcumin formulation efficacy in management of mild to moderate hospitalized coronavirus disease-19 patients: an open label nonrandomized clinical trial. Phytotherapy Research, 35(5), 2616–2623. https://doi.org/10.1002/ptr.7004
94. Tahmasebi, S., El-Esawi, M. A., Mahmoud, Z. H., & et al. (2021). Immunomodulatory effects of nanocurcumin on Th17 cell responses in mild and severe COVID-19 patients. Journal of Cellular Physiology, 236(7), 5325–5338. https://doi.org/10.1002/jcp.30233
95. Attia, G. H., Moemen, Y. S., Youns, M., & et al. (2021). Antiviral zinc oxide nanoparticles mediated by hesperidin and in silico comparison study between antiviral phenolics as anti-SARS-CoV-2. Colloids and Surfaces B: Biointerfaces, 203, Article 111724. https://doi.org/10.1016/j.colsurfb.2021.111724
96. Al-Sanea, M. M., Abelyan, N., Abdelgawad, M. A., & et al. (2021). Strawberry and ginger silver nanoparticles as potential inhibitors for SARS-CoV-2 assisted by in silico modeling and metabolic profiling. Antibiotics, 10(7), Article 824. https://doi.org/10.3390/antibiotics10070824
97. Ngan, L. T., Jang, M. J., Kwon, M. J., & et al. (2015). Antiviral activity and possible mechanism of action of constituents identified in Paeonia lactiflora root toward human rhinoviruses. PLOS ONE, 10(4), Article e0121629. https://doi.org/10.1371/journal.pone.0121629
98. Ho, T. Y., Wu, S. L., Chen, J. C., & et al. (2007). Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction. Antiviral Research, 74(2), 92–101. https://doi.org/10.1016/j.antiviral.2006.04.014
99. Zhao, Z., Xiao, Y., Xu, L., & et al. (2021). Glycyrrhizic acid nanoparticles as antiviral and anti-inflammatory agents for COVID-19 treatment. ACS Applied Materials & Interfaces, 13(18), 20995–21006. https://doi.org/10.1021/acsami.1c02755
100. Puntasecca, C. J., King, C. H., & LaBeaud, A. D. (2021). Measuring the global burden of chikungunya and Zika viruses: a systematic review. PLOS Neglected Tropical Diseases, 15(3), Article e0009055. https://doi.org/10.1371/journal.pntd.0009055
101. Triastuti, N. J. (2023). The comparison of dengue haemorrhagic fever cases in Indonesia during the COVID-19 pandemic. Journal of Medical Chemical Sciences, 6(6), 1336–1343. https://doi.org/10.26655/jmchemsci.2023.6.13
102. Nazni, W. A., Hoffmann, A. A., NoorAfizah, A., & et al. (2019). Establishment of Wolbachia strain wAlbB in Malaysian populations of Aedes aegypti for dengue control. Current Biology, 29(24), 4241–4248.e5. https://doi.org/10.1016/j.cub.2019.11.026